ArticleP & T : a peer-reviewed journal for formulary management2009
Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia.
Article in P & T : a peer-reviewed journal for formulary management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 72 citations in OpenAlex.
- Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study.International journal of molecular sciences · 2017Trial
- A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLATrials · 2017Trial
- Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.European journal of nutrition · 2013Trial
- Red yeast rice with monacolin K for the improvement of hyperlipidemia: A narrative review.World journal of clinical cases · 2025Review
- Successful Resolution of Suspected Red Yeast Rice-induced Nephropathy.Internal medicine (Tokyo, Japan) · 2025Article
- Fanconi syndrome following administration of oral supplements containing red yeast rice: several months follow-up of three cases.CEN case reports · 2025Article
- Chemical Complexity of Food and Implications for Therapeutics.The New England journal of medicine · 2025Review
- Microbial Fermentation in Food and Beverage Industries: Innovations, Challenges, and Opportunities.Foods (Basel, Switzerland) · 2025Review
- The Anatomical and Physiological Knowledge of theMedical acupuncture · 2024Review
- Studies Regarding Antimicrobial Properties of Some Microbial Polyketides Derived fromAntibiotics (Basel, Switzerland) · 2024Article
- Natural product-based treatment potential for type 2 diabetes mellitus and cardiovascular disease.World journal of diabetes · 2024Article
- Decoding the Intricacies of Statin-Associated Muscle Symptoms.Current rheumatology reports · 2024Review
- Treatment of Immune-Mediated Necrotizing Myopathy.Current treatment options in rheumatology · 2023Article
- Drastic Synergy of Lovastatin andNutrients · 2023Article
- Evidence-Based Pharmaceutical Care in Community Pharmacies: A Survey of 595 French Pharmacists.Pharmacy (Basel, Switzerland) · 2023Article
- The Questionable Quality Profile of Food Supplements: The Case of Red Yeast Rice Marketed Products.Foods (Basel, Switzerland) · 2023Article
- Rhabdomyolysis Related to Red Yeast Rice Ingestion.Cureus · 2023Article
- Pediatric immune-mediated necrotizing myopathy.Frontiers in neurology · 2023Review
- Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds.International journal of molecular sciences · 2022Review
- Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice.Chinese medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red yeast rice is a Chinese fermented rice product (Monascus purpureus) that some have claimed improves blood circulation by decreasing cholesterol and triglyceride levels in humans. The supplement contains naturally occurring monacolin K, the active ingredient found in Merck's prescription agent lovastatin (Mevacor). Lovastatin is associated with various adverse effects such as myopathy and abnormal liver function test results, which can lead to serious problems if patients are not monitored and treated. The inclusion of lovastatin in red yeast rice and the lack of dietary supplement regulation by the FDA raise safety concerns for health care professionals as well as for patients. Studies have shown that red yeast rice products can be beneficial in lowering serum cholesterol levels, but they are not without risk. Furthermore, product uniformity, purity, labeling, and safety cannot be guaranteed.
Indexed as
Identifiers
19572049PMC2697909W2116276162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.